PT1264599E - Péptidos derivados de tnf para utilização no tratamento de edema - Google Patents

Péptidos derivados de tnf para utilização no tratamento de edema Download PDF

Info

Publication number
PT1264599E
PT1264599E PT02077256T PT02077256T PT1264599E PT 1264599 E PT1264599 E PT 1264599E PT 02077256 T PT02077256 T PT 02077256T PT 02077256 T PT02077256 T PT 02077256T PT 1264599 E PT1264599 E PT 1264599E
Authority
PT
Portugal
Prior art keywords
tnf
oedema
alpha
present
derived peptides
Prior art date
Application number
PT02077256T
Other languages
English (en)
Portuguese (pt)
Inventor
Rudolf Lucas
Patrick De Baetselier
Jerome Pugin
Alain Bloc
Lucie Fransen
Original Assignee
Rudolf Lucas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rudolf Lucas filed Critical Rudolf Lucas
Publication of PT1264599E publication Critical patent/PT1264599E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/191Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT02077256T 1998-08-14 1999-08-10 Péptidos derivados de tnf para utilização no tratamento de edema PT1264599E (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98870180 1998-08-14
EP98870198 1998-09-18
EP98870222 1998-10-21

Publications (1)

Publication Number Publication Date
PT1264599E true PT1264599E (pt) 2008-01-07

Family

ID=27239778

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02077256T PT1264599E (pt) 1998-08-14 1999-08-10 Péptidos derivados de tnf para utilização no tratamento de edema

Country Status (20)

Country Link
US (2) US20030105021A1 (https=)
EP (3) EP1264599B1 (https=)
JP (1) JP4542266B2 (https=)
CN (1) CN1181886C (https=)
AT (2) ATE395072T1 (https=)
AU (1) AU764992B2 (https=)
BR (1) BR9912899A (https=)
CA (1) CA2334941C (https=)
CZ (1) CZ302862B6 (https=)
DE (2) DE69938743D1 (https=)
DK (1) DK1264599T3 (https=)
ES (1) ES2296872T3 (https=)
HU (1) HU227661B1 (https=)
IL (2) IL141064A0 (https=)
NZ (1) NZ509604A (https=)
PL (1) PL203706B1 (https=)
PT (1) PT1264599E (https=)
TR (1) TR200100338T2 (https=)
WO (1) WO2000009149A1 (https=)
ZA (1) ZA200100656B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU764992B2 (en) 1998-08-14 2003-09-04 LUCAS, Rudolf Dr. TNF-derived peptides for use in treating oedema
CA2575513C (en) 2004-08-06 2014-09-16 Altana Pharma Ag Composition comprising a pulmonary surfactant and a tnf-derived peptide
EP2009023A1 (en) * 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
AT506150B1 (de) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Zyklisches und cystein-freies peptid
AT506151B1 (de) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Fusionsprotein
AT507953B1 (de) * 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität
AT509267A1 (de) * 2010-01-14 2011-07-15 Apeptico Forschung & Entwicklung Gmbh Organische verbindungen zur regulierung von vektoriellen ionenkanälen
DK2397151T3 (en) * 2010-06-21 2015-05-18 Apeptico Forschung & Entwicklung Gmbh The treatment of the vascular complications of diabetes
AT510585B1 (de) * 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase
US11161881B2 (en) * 2010-11-18 2021-11-02 Apeptico Forschung Und Entwicklung Gmbh Composition comprising a peptide and an inhibitor of viral neuraminidase
EP2679239A1 (de) * 2012-06-28 2014-01-01 Apeptico Forschung und Entwicklung GmbH Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit
US12004506B2 (en) 2013-04-23 2024-06-11 Apeptico Forschung Und Entwicklung Gmbh Pharmaceutical composition comprising a cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment
KR102113501B1 (ko) * 2013-04-23 2020-05-22 아펩티코 포어슝 운트 엔트빅크룽 게엠베하 식 x₁-gqretpegaeakpwy-x₂의 고리 펩티드를 포함하는 제약 조성물 및 체외 폐 치료를 위한 사용
WO2015140125A2 (en) 2014-03-18 2015-09-24 Apeptico Forschung Und Entwicklung Gmbh Dry-powder peptide medicament
CN110613838A (zh) * 2018-06-19 2019-12-27 姜石松 增强细胞通透性的多肽及其应用
CN119264211A (zh) 2018-08-27 2025-01-07 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
EP4051307B1 (en) 2020-05-08 2023-02-01 APEPTICO Forschung und Entwicklung GmbH Peptide for prevention or treatment of covid-19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE384179C (de) * 1921-04-07 1923-10-27 Ludwig Weil Dr Laufrad fuer Kreiselpumpen und -geblaese
DE3841759A1 (de) 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
US5891679A (en) 1993-02-03 1999-04-06 N.V. Innogenetics S.A. TNF-alpha muteins and a process for preparing them
AU764992B2 (en) 1998-08-14 2003-09-04 LUCAS, Rudolf Dr. TNF-derived peptides for use in treating oedema

Also Published As

Publication number Publication date
EP1247531A2 (en) 2002-10-09
EP1105152A1 (en) 2001-06-13
IL141064A0 (en) 2002-02-10
ZA200100656B (en) 2005-06-29
US20030105021A1 (en) 2003-06-05
HU227661B1 (hu) 2011-10-28
EP1264599A1 (en) 2002-12-11
JP2002522508A (ja) 2002-07-23
DE69937206D1 (de) 2007-11-08
TR200100338T2 (tr) 2001-12-21
US20030185791A1 (en) 2003-10-02
ATE374039T1 (de) 2007-10-15
CN1181886C (zh) 2004-12-29
AU5620999A (en) 2000-03-06
HUP0103117A3 (en) 2004-03-01
CN1312724A (zh) 2001-09-12
AU764992B2 (en) 2003-09-04
EP1264599B1 (en) 2007-09-26
DE69937206T2 (de) 2008-06-19
EP1247531B1 (en) 2008-05-14
EP1247531A3 (en) 2002-12-18
PL345997A1 (en) 2002-01-14
HUP0103117A2 (hu) 2001-12-28
NZ509604A (en) 2003-05-30
ES2296872T3 (es) 2008-05-01
CZ2001538A3 (cs) 2001-08-15
BR9912899A (pt) 2001-05-08
WO2000009149A1 (en) 2000-02-24
HK1051805A1 (en) 2003-08-22
ATE395072T1 (de) 2008-05-15
DE69938743D1 (de) 2008-06-26
IL141064A (en) 2009-09-01
CZ302862B6 (cs) 2011-12-21
DK1264599T3 (da) 2008-02-04
PL203706B1 (pl) 2009-11-30
JP4542266B2 (ja) 2010-09-08
CA2334941C (en) 2011-08-09
US7258861B2 (en) 2007-08-21
CA2334941A1 (en) 2000-02-24

Similar Documents

Publication Publication Date Title
PL345997A1 (en) Tnf-derived peptides for use in treating oedema
HUT54213A (en) Process for the enzymatic removal of n-terminal sequence of proteins
IL161591A (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
AU2672900A (en) Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides
IL187907A0 (en) Analogues of glp-1 and uses thereof
IL143481A0 (en) Glp-1 analogues
JP2001520045A5 (https=)
EP0188400A3 (en) Oligopeptides, intermediates and process for their preparation
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
WO2002015922A3 (en) New uses for amino acid anticonvulsants for treatment of pain
DE60217326D1 (de) Von neurofilamentproteinen abgeleitete peptide und deren medizinische verwendung
GB2367061A (en) Peptides
AR002742A1 (es) Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn
EP0318935A3 (en) Substituted alpha-amino acids having pharmaceutical activity
ATE198987T1 (de) Behandlung von tropikalischer spastischer paresis mit peptide t
ATE409492T1 (de) Zusammensetzung zur vermeidung und behandlung von cellulitis
DK0769056T3 (da) Ikke-splejsende verianter af gp350/220
ATE310091T1 (de) Carboxypeptidasen aus aspergillus oryzae und diese kodierende nukleinsäuren
DE69526972D1 (de) Verwendung von Gabapentin in der Behandlung vonAngst - und Panikstörungen
ATE342352T1 (de) Entwurf und verwendung von verbesserten zink- chelatbildenden peptiden zur regulation von matrix-metalloproteinasen
GB9604518D0 (en) Novel compounds